NuVasive reports increased net sales in third-quarter 2022 financial results
NuVasive Inc. has announced increased net sales and a record quarter for cervical net sales for its C360 portfolio in its third-quarter 2022 financial results, according to a company press release.
The company reported $295.3 million in total net sales, which is a 12.9% increase on a constant currency basis compared with the third quarter of 2021. The company also reported a generally accepted accounting principles gross profit of $214.4 million compared with $182.2 million in the prior year period.
“The strategic investments we've made in product and technology innovation are delivering continued above-market growth — as demonstrated by double-digit growth in net sales on a constant currency basis,” Chris Barry, CEO of NuVasive, said in the release. “Despite the challenging macro environment, we continue to execute as evidenced by our top- and bottom-line performance in the quarter. I remain excited about the future of NuVasive — and our commitment to deliver meaningful innovation to support our surgeons, providers and patients,” he said.
Read more about